Identifying the emerging role of adipokine as a diagnostic and prognostic biomarker of renal cell carcinoma

Seock Hwan Choi; So Young Chun; Tae Hwan Kim; Tae Gyun Kwon

doi:10.1016/j.urolonc.2016.01.007

Identifying the emerging role of adipokine as a diagnostic and prognostic biomarker of renal cell carcinoma

Seock Hwan Choi, So Young Chun, Tae Hwan Kim, Tae Gyun Kwon

Department of Medicine

Kyungpook National University

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Objective: To assess the association and prognostic value of adipokines (adipocyte-secreted peptide hormones) in renal cell carcinoma (RCC). Materials and methods: Plasma samples from 54 RCC patients and 25 age-matched healthy controls were analyzed for levels of adipokines (adiponectin, leptin, retinol-binding protein 4 [RBP4], and nicotinamide phosphoribosyltransferase [NAMPT]). Baseline characteristics and adipokine levels were compared between patients and controls. The effect of adipokine levels on RCC severity was also investigated. Results: Medians (patients/controls) were body mass index: 24.6/23.5 kg/m², serum glucose: 111/93 mg/dl, and high-density lipoprotein: 43/53 mg/dl, and significantly differed between the 2 groups. Median levels (patients/controls) of adipokines were adiponectin: 4.36/8.84 ug/ml, leptin: 2.91/2.92 ng/ml, RBP4: 30.27/16.17 ug/ml and NAMPT: 2.26/2.06 ng/ml; adiponectin, RBP4 and NAMPT (but not leptin) were independently associated with RCC in logistic regression models, and only serum NAMPT was significantly associated with RCC severity (T stage). Conclusions: Lower plasma levels of adiponectin, and higher levels of RBP4 and NAMPT, are strongly correlated with RCC, indicating that these adipokines could be used as biomarkers for RCC.

Original language	English
Pages (from-to)	259.e15-259.e19
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	34
Issue number	6
DOIs	https://doi.org/10.1016/j.urolonc.2016.01.007
State	Published - 1 Jun 2016

Keywords

Adipokine
Biomarker
Obesity
Renal cell carcinoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.urolonc.2016.01.007

Cite this

@article{75d3b05375c0461eadb998d24080553a,

title = "Identifying the emerging role of adipokine as a diagnostic and prognostic biomarker of renal cell carcinoma",

abstract = "Objective: To assess the association and prognostic value of adipokines (adipocyte-secreted peptide hormones) in renal cell carcinoma (RCC). Materials and methods: Plasma samples from 54 RCC patients and 25 age-matched healthy controls were analyzed for levels of adipokines (adiponectin, leptin, retinol-binding protein 4 [RBP4], and nicotinamide phosphoribosyltransferase [NAMPT]). Baseline characteristics and adipokine levels were compared between patients and controls. The effect of adipokine levels on RCC severity was also investigated. Results: Medians (patients/controls) were body mass index: 24.6/23.5 kg/m2, serum glucose: 111/93 mg/dl, and high-density lipoprotein: 43/53 mg/dl, and significantly differed between the 2 groups. Median levels (patients/controls) of adipokines were adiponectin: 4.36/8.84 ug/ml, leptin: 2.91/2.92 ng/ml, RBP4: 30.27/16.17 ug/ml and NAMPT: 2.26/2.06 ng/ml; adiponectin, RBP4 and NAMPT (but not leptin) were independently associated with RCC in logistic regression models, and only serum NAMPT was significantly associated with RCC severity (T stage). Conclusions: Lower plasma levels of adiponectin, and higher levels of RBP4 and NAMPT, are strongly correlated with RCC, indicating that these adipokines could be used as biomarkers for RCC.",

keywords = "Adipokine, Biomarker, Obesity, Renal cell carcinoma",

author = "Choi, {Seock Hwan} and Chun, {So Young} and Kim, {Tae Hwan} and Kwon, {Tae Gyun}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.urolonc.2016.01.007",

language = "English",

volume = "34",

pages = "259.e15--259.e19",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Identifying the emerging role of adipokine as a diagnostic and prognostic biomarker of renal cell carcinoma

AU - Choi, Seock Hwan

AU - Chun, So Young

AU - Kim, Tae Hwan

AU - Kwon, Tae Gyun

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objective: To assess the association and prognostic value of adipokines (adipocyte-secreted peptide hormones) in renal cell carcinoma (RCC). Materials and methods: Plasma samples from 54 RCC patients and 25 age-matched healthy controls were analyzed for levels of adipokines (adiponectin, leptin, retinol-binding protein 4 [RBP4], and nicotinamide phosphoribosyltransferase [NAMPT]). Baseline characteristics and adipokine levels were compared between patients and controls. The effect of adipokine levels on RCC severity was also investigated. Results: Medians (patients/controls) were body mass index: 24.6/23.5 kg/m2, serum glucose: 111/93 mg/dl, and high-density lipoprotein: 43/53 mg/dl, and significantly differed between the 2 groups. Median levels (patients/controls) of adipokines were adiponectin: 4.36/8.84 ug/ml, leptin: 2.91/2.92 ng/ml, RBP4: 30.27/16.17 ug/ml and NAMPT: 2.26/2.06 ng/ml; adiponectin, RBP4 and NAMPT (but not leptin) were independently associated with RCC in logistic regression models, and only serum NAMPT was significantly associated with RCC severity (T stage). Conclusions: Lower plasma levels of adiponectin, and higher levels of RBP4 and NAMPT, are strongly correlated with RCC, indicating that these adipokines could be used as biomarkers for RCC.

AB - Objective: To assess the association and prognostic value of adipokines (adipocyte-secreted peptide hormones) in renal cell carcinoma (RCC). Materials and methods: Plasma samples from 54 RCC patients and 25 age-matched healthy controls were analyzed for levels of adipokines (adiponectin, leptin, retinol-binding protein 4 [RBP4], and nicotinamide phosphoribosyltransferase [NAMPT]). Baseline characteristics and adipokine levels were compared between patients and controls. The effect of adipokine levels on RCC severity was also investigated. Results: Medians (patients/controls) were body mass index: 24.6/23.5 kg/m2, serum glucose: 111/93 mg/dl, and high-density lipoprotein: 43/53 mg/dl, and significantly differed between the 2 groups. Median levels (patients/controls) of adipokines were adiponectin: 4.36/8.84 ug/ml, leptin: 2.91/2.92 ng/ml, RBP4: 30.27/16.17 ug/ml and NAMPT: 2.26/2.06 ng/ml; adiponectin, RBP4 and NAMPT (but not leptin) were independently associated with RCC in logistic regression models, and only serum NAMPT was significantly associated with RCC severity (T stage). Conclusions: Lower plasma levels of adiponectin, and higher levels of RBP4 and NAMPT, are strongly correlated with RCC, indicating that these adipokines could be used as biomarkers for RCC.

KW - Adipokine

KW - Biomarker

KW - Obesity

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84960981647&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2016.01.007

DO - 10.1016/j.urolonc.2016.01.007

M3 - Article

C2 - 26992934

AN - SCOPUS:84960981647

SN - 1078-1439

VL - 34

SP - 259.e15-259.e19

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 6

ER -

Identifying the emerging role of adipokine as a diagnostic and prognostic biomarker of renal cell carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this